Delcath Systems, Inc. (DCTH)

Market Cap	532.97M +37.3%
Revenue (ttm)	95.42M +35.8%
Net Income	532,000 -76.2%
EPS	0.01 -71.9%
Shares Out	34.70M
PE Ratio	1,001.83
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	190,108
Open	15.07
Previous Close	15.04
Day's Range	14.95 - 15.40
52-Week Range	8.12 - 17.42
Beta	0.60
Analysts	Strong Buy
Price Target	24.00 (+56.25%)
Est. Earnings	Nov 3, 2026

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 156
• Stock Exchange: Nasdaq
• Ticker Symbol: DCTH
• Website: https://www.delcath.com

Analyst Summary

According to 5 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $24.0, which is an increase of 56.25% from the latest price.

Price Target

$24.0

(56.25% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error